文献速递淋巴瘤造血干细胞移植与细胞治疗

同种异体嵌合抗原受体T细胞产品cemacabtagene ansegedleucel/ALLO-501治疗复发/难治性大B细胞淋巴瘤:ALPHA2/ALPHA临床研究的I期经验

Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies.
PubMed 文献 · J Clin Oncol · 2025-02-13

在ALPHA2/ALPHA研究中,33例CD19 CAR T初治的复发/难治性大B细胞淋巴瘤患者接受健康供者来源的同种异体CD19 CAR T细胞(cema-cel/ALLO-501)治疗,先经3天氟达拉滨、环磷酰胺和ALLO-647淋巴清除。总缓解率58%,完全缓解率42%,完全缓解患者中位缓解持续时间23.1个月,未报告移植物抗宿主病、免疫效应细胞相关神经毒性综合征或≥3级细胞因子释放综合征。

要点

  • 33例CD19 CAR T初治的复发/难治性大B细胞淋巴瘤患者接受同种异体CD19 CAR T细胞治疗。
  • 总缓解率58%,完全缓解率42%,完全缓解患者中位缓解持续时间23.1个月。
  • 未报告移植物抗宿主病、免疫效应细胞相关神经毒性综合征或≥3级细胞因子释放综合征。

核心结论

  • 同种异体CD19 CAR T细胞在CD19 CAR T初治的复发/难治性大B细胞淋巴瘤患者中显示出有前景的总缓解率和持久完全缓解率,安全性可控,支持对cema-cel在LBCL患者中开展进一步评估。

研究设计与样本

  • ALPHA2/ALPHA研究为I期研究,评估同种异体CD19 CAR T细胞在CD19 CAR T初治的复发/难治性大B细胞淋巴瘤患者中的安全性和有效性。
  • 患者接受健康供者来源、人类白细胞抗原不匹配的cema-cel/ALLO-501,先经3天淋巴清除方案:氟达拉滨30 mg/m2每日一次、环磷酰胺300或500 mg/m2每日一次,以及递增剂量的抗CD52单克隆抗体ALLO-647。
  • 截至2024年9月26日,33例CD19 CAR T初治的LBCL患者接受同种异体CAR T细胞治疗,中位年龄66岁,中位既往治疗线数3。

主要发现

  • 输注后观察到CAR T细胞扩增,持久性观察到长达4个月。
  • 总缓解率和完全缓解率分别为58%和42%。
  • 完全缓解患者的中位缓解持续时间为23.1个月。
  • 最常见的治疗中出现的不良事件为血液学毒性。
  • 未报告移植物抗宿主病、免疫效应细胞相关神经毒性综合征或≥3级细胞因子释放综合征病例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Off-the-shelf, allogeneic CD19 chimeric antigen receptor (CAR) T-cell products may improve access to treatment versus autologous ones. We report the phase I experience of the allogeneic CD19 CAR T-cell product cemacabtagene ansegedleucel (cema-cel) and its predecessor, ALLO-501, in CD19 CAR T-naïve patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). METHODS: In the ALPHA2/ALPHA studies, the safety and efficacy of allogeneic CD19 CAR T cells were evaluated in CD19 CAR T treatment-naïve patients with R/R LBCL. Patients received healthy donor-derived, human leukocyte antigen-unmatched cema-cel/ALLO-501 following a 3-day lymphodepletion regimen of fludarabine (30 mg/m2 once daily), cyclophosphamide (300 or 500 mg/m2 once daily), and escalating doses of the anti-CD52 monoclonal antibody, ALLO-647. RESULTS: As of September 26, 2024, 33 CD19 CAR T-naïve patients with LBCL (median age, 66 years; median number of previous therapies, 3) received allogeneic CAR T cells. CAR T-cell expansion was observed following infusion, with persistence observed up to 4 months. The overall and complete response (CR) rates were 58% and 42%, respectively; the median duration of response in patients with a CR was 23.1 months. The most common treatment-emergent adverse events were hematologic toxicities. No cases of graft-versus-host disease, immune effector cell-associated neurotoxicity syndrome, or grade ≥3 cytokine release syndrome were reported. CONCLUSION: Allogeneic CD19 CAR T cells demonstrated promising overall and durable CR rates with a manageable safety profile in CD19 CAR T-naïve patients with R/R LBCL, supporting additional evaluation of cema-cel in patients with LBCL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Locke FL, Munoz JL, Tees MT, et al. Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies. J Clin Oncol. 2025. PMID: 39946666. doi:10.1200/JCO-24-01933

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。